drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cell)
drug_description
Investigational autologous anti-CD22 CAR T-cell therapy infused 28–42 days after tisagenlecleucel; engineered T cells target CD22 to eliminate residual or antigen-shifted B-ALL via CAR-mediated T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor targeting CD22 on B-lineage cells. Upon CD22 binding, the CAR (CD3z with costimulation) activates the T cell, driving expansion, cytokine release, and perforin/granzyme-mediated cytotoxicity to eliminate CD22-positive malignant B cells, including residual or antigen-shifted blasts after CD19-directed therapy.
drug_name
Autologous CD22 CAR T cells (CD22CART)
nct_id_drug_ref
NCT06408194